Madrigal Pharmaceuticals News and Activities

Madrigal Pharmaceuticals is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Madrigal Pharmaceuticals is a company listed under the stock ticker MDGL (US).

View the org chart displaying its 48 main executives

Most searched biographies at Madrigal Pharmaceuticals

• Bill Sibold, Chief Executive Officer and Director
• Paul Friedman, Director
• Daniel Brennan, Director

Popular executive movements at Madrigal Pharmaceuticals

• Dan Wolf has joined the company as Senior Director, Clinical Development  (posted on May 20 2026).
• Michelle Didomenico has joined the company as Senior Director, Talent Access  (posted on January 15 2026).
• Rita Thakkar has joined the company as Senior Vice President and Chief Accounting Officer  (posted on December 19 2025).

Click here to view some more movements at Madrigal Pharmaceuticals

Create your alert
to follow the executive moves at Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Madrigal Pharmaceuticals

• Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting® | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 | Madrigal Pharmaceuticals.
• Press Releases | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom) | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference | Madrigal Pharmaceuticals.
• View more press releases Close

Social media about Madrigal Pharmaceuticals

• Madrigal Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Madrigal Pharmaceuticals on LinkedIn, X (Twitter) & YouTube